Metabolic Response to NAD Depletion across Cell Lines Is Highly Variable.

by Yang Xiao, Mandy Kwong, Anneleen Daemen, Marcia Belvin, Xiaorong Liang, Georgia Hatzivassiliou, Thomas O'Brien
Published 2016-01-01

Dependence of Tumor Cell Lines and Patient-Derived Tumors on the NAD Salvage Pathway Renders Them Sensitive to NAMPT Inhibition with GNE-618

by Yang Xiao, Kristi Elkins, Jenni K Durieux, Leslie Lee, Jason Oeh, Lulu X Yang, Xiaorong Liang, Chris DelNagro, Jarrod Tremayne, Mandy Kwong, Bianca M Liederer, Peter K Jackson, Lisa D Belmont, Deepak Sampath, Thomas O'Brien
Published 2013-10-01

Supplementation of Nicotinic Acid with NAMPT Inhibitors Results in Loss of In Vivo Efficacy in NAPRT1-Deficient Tumor Models

by Thomas O'Brien, Jason Oeh, Yang Xiao, Xiaorong Liang, Alexander Vanderbilt, Ann Qin, Lulu Yang, Leslie B. Lee, Justin Ly, Ely Cosino, Jennifer A. LaCap, Annie Ogasawara, Simon Williams, Michelle Nannini, Bianca M. Liederer, Peter Jackson, Peter S. Dragovich, Deepak Sampath
Published 2013-12-01

Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors

by Asha Nayak-Kapoor, Zhonglin Hao, Ramses Sadek, Robin Dobbins, Lisa Marshall, Nicholas N. Vahanian, W. Jay Ramsey, Eugene Kennedy, Mario R. Mautino, Charles J. Link, Ray S. Lin, Stephanie Royer-Joo, Xiaorong Liang, Laurent Salphati, Kari M. Morrissey, Sami Mahrus, Bruce McCall, Andrea Pirzkall, David H. Munn, John E. Janik, Samir N. Khleif
Published 2018-06-01